Market Closed -
Nasdaq
21:00:00 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
9.11
USD
|
+0.89%
|
|
+2.82%
|
-18.44%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
362.5
|
484.4
|
265.1
|
592.4
|
1,041
|
867.5
|
-
|
-
|
Enterprise Value (EV)
1 |
362.5
|
484.4
|
265.1
|
592.4
|
487
|
466.3
|
677.5
|
643.8
|
P/E ratio
|
-1.07
x
|
-7.91
x
|
-2.92
x
|
-4.34
x
|
-5.59
x
|
-4.12
x
|
-3.35
x
|
-3.51
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
925
x
|
397
x
|
33.7
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
497
x
|
310
x
|
25
x
|
EV / EBITDA
|
-13.6
x
|
-9.83
x
|
-2.96
x
|
-5.8
x
|
-3.22
x
|
-2.1
x
|
-2.49
x
|
-2.11
x
|
EV / FCF
|
-14.2
x
|
-10.4
x
|
-3.45
x
|
-7.31
x
|
-3.77
x
|
-2.39
x
|
-2.73
x
|
-2.41
x
|
FCF Yield
|
-7.06%
|
-9.57%
|
-29%
|
-13.7%
|
-26.5%
|
-41.9%
|
-36.6%
|
-41.6%
|
Price to Book
|
-
|
-
|
-
|
-
|
1.48
x
|
2.26
x
|
5.32
x
|
5.54
x
|
Nbr of stocks (in thousands)
|
13,789
|
19,879
|
20,282
|
46,537
|
93,206
|
95,225
|
-
|
-
|
Reference price
2 |
26.29
|
24.37
|
13.07
|
12.73
|
11.17
|
9.110
|
9.110
|
9.110
|
Announcement Date
|
18/03/20
|
24/03/21
|
24/03/22
|
10/03/23
|
29/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
0.9375
|
2.188
|
25.77
|
EBITDA
1 |
-26.62
|
-49.3
|
-89.66
|
-102.2
|
-151.2
|
-222.3
|
-272.4
|
-305.4
|
EBIT
1 |
-26.64
|
-49.36
|
-89.74
|
-102.2
|
-151.2
|
-208
|
-254.8
|
-270
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-22,183.18%
|
-11,649.17%
|
-1,047.74%
|
Earnings before Tax (EBT)
1 |
-57.2
|
-49.56
|
-90.27
|
-102
|
-138.3
|
-191.4
|
-247.6
|
-272.5
|
Net income
1 |
-57.42
|
-49.5
|
-90.12
|
-102
|
-142.2
|
-194
|
-254.3
|
-274.3
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-20,690.68%
|
-11,623.12%
|
-1,064.58%
|
EPS
2 |
-24.49
|
-3.080
|
-4.480
|
-2.930
|
-2.000
|
-2.213
|
-2.716
|
-2.597
|
Free Cash Flow
1 |
-25.6
|
-46.37
|
-76.84
|
-81.1
|
-129.2
|
-195.3
|
-248.2
|
-267.5
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-20,827.2%
|
-11,348.01%
|
-1,038.23%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18/03/20
|
24/03/21
|
24/03/22
|
10/03/23
|
29/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.625
|
0.625
|
-
|
EBITDA
|
-
|
-
|
-
|
-24.72
|
-
|
-
|
-
|
-
|
-39.34
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-28.21
|
-26.24
|
-25.11
|
-24.74
|
-27.04
|
-25.36
|
-28.52
|
-42.13
|
-39.34
|
-41.21
|
-45.74
|
-50.5
|
-54.87
|
-60.24
|
-59.83
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-8,778.84%
|
-9,638.05%
|
-
|
Earnings before Tax (EBT)
1 |
-28.33
|
-26.44
|
-25.56
|
-25.05
|
-26.8
|
-24.59
|
-28.84
|
-38.39
|
-34.72
|
-36.37
|
-41.48
|
-45.95
|
-51.43
|
-57.48
|
-55.88
|
Net income
1 |
-28.33
|
-63.83
|
-25.56
|
-25.05
|
-26.8
|
-24.6
|
-28.84
|
-38.39
|
-34.72
|
-40.24
|
-41.82
|
-46.86
|
-51.88
|
-57.36
|
-55.88
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-8,300.04%
|
-9,177.3%
|
-
|
EPS
2 |
-1.410
|
-1.300
|
-1.260
|
-1.230
|
-0.5700
|
-0.4800
|
-0.5400
|
-0.5200
|
-0.4500
|
-0.5000
|
-0.4695
|
-0.5246
|
-0.5775
|
-0.6339
|
-0.5935
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/11/21
|
24/03/22
|
11/05/22
|
11/08/22
|
10/11/22
|
10/03/23
|
08/05/23
|
09/08/23
|
09/11/23
|
29/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
554
|
401
|
190
|
224
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-25.6
|
-46.4
|
-76.8
|
-81.1
|
-129
|
-195
|
-248
|
-268
|
ROE (net income / shareholders' equity)
|
-155%
|
-33.8%
|
-54.8%
|
-73.5%
|
-41.3%
|
-46.2%
|
-90.1%
|
-173%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
-
|
7.540
|
4.020
|
1.710
|
1.640
|
Cash Flow per Share
2 |
-10.90
|
-2.870
|
-3.820
|
-0.7800
|
-1.820
|
-2.450
|
-3.140
|
-
|
Capex
1 |
0.14
|
0.13
|
0.06
|
0.01
|
0
|
1.53
|
2.03
|
3.06
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
163.71%
|
92.89%
|
11.87%
|
Announcement Date
|
18/03/20
|
24/03/21
|
24/03/22
|
10/03/23
|
29/02/24
|
-
|
-
|
-
|
Last Close Price
9.11
USD Average target price
31.78
USD Spread / Average Target +248.82% Consensus |
1st Jan change
|
Capi.
|
---|
| -18.44% | 867M | | +2.97% | 108B | | +10.21% | 104B | | +1.57% | 22.33B | | -12.77% | 22.19B | | -7.05% | 18.69B | | -37.64% | 17.74B | | -6.50% | 17.64B | | +6.00% | 14.05B | | +37.20% | 12.51B |
Bio Therapeutic Drugs
|